Zubeyir H. Gun

Pediatric Endocrinology | Medical Genetics

1800 Orleans St
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 5 publications

A phase 2 trial of burosumab for treatment of fibroblast growth factor-23 mediated hypophosphatemia in children and adults with fibrous dysplasia.

A phase 2 trial of burosumab for treatment of fibroblast growth factor-23 mediated hypophosphatemia in children and adults with fibrous dysplasia.

Journal: medRxiv : the preprint server for health sciences

Published: January 02, 2026

Gαs variant detection discerns skeletal cell types involved in fibrous dysplasia pathogenesis.

Gαs variant detection discerns skeletal cell types involved in fibrous dysplasia pathogenesis.

Journal: Bone

Published: October 01, 2025

A phase 2 trial of burosumab for treatment of fibroblast growth factor-23-mediated hypophosphatemia in children and adults with fibrous dysplasia.

A phase 2 trial of burosumab for treatment of fibroblast growth factor-23-mediated hypophosphatemia in children and adults with fibrous dysplasia.

Journal: Bone research

Published: August 20, 2025

Fibrous dysplasia in children and its management.

Fibrous dysplasia in children and its management.

Journal: Current opinion in endocrinology, diabetes, and obesity

Published: November 27, 2023

Serum Phosphorus as a Driver of Skeletal Morbidity in Fibrous Dysplasia.

Serum Phosphorus as a Driver of Skeletal Morbidity in Fibrous Dysplasia.

Journal: The Journal of clinical endocrinology and metabolism

Published: June 30, 2023

Showing 1-5 of 5

Last Updated: 09/26/2026